These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8174443)

  • 1. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems.
    Olsen CL; Chan E; Turner DS; Iravani M; Nagy M; Selam JL; Wong ND; Waxman K; Charles MA
    Diabetes Care; 1994 Mar; 17(3):169-76. PubMed ID: 8174443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices.
    Jeandidier N; Boivin S; Sapin R; Rosart-Ortega F; Uring-Lambert B; Réville P; Pinget M
    Diabetologia; 1995 May; 38(5):577-84. PubMed ID: 7489841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps. Metabolic consequences.
    Lassmann-Vague V; Belicar P; Raccah D; Vialettes B; Sodoyez JC; Vague P
    Diabetes Care; 1995 Apr; 18(4):498-503. PubMed ID: 7497859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of antigenicity of Hoechst 21PH insulin using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients.
    Jeandidier N; Boullu S; Busch-Brafin MS; Chabrier G; Sapin R; Gasser F; Pinget M
    Diabetes Care; 2002 Jan; 25(1):84-8. PubMed ID: 11772906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with intraperitoneal insulin infusion from implantable programmable systems in type 1 (insulin-dependent) diabetes mellitus previously treated by external pumps.
    Renard E; Lauton D; Bonifacj C; Costalat G; Jacques D; Bringer J; Jaffiol C
    Diabete Metab; 1993; 19(4):364-71. PubMed ID: 8293863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of programmable implantable insulin delivery systems.
    Olsen CL; Liu G; Iravani M; Nguyen S; Khourdadjian K; Turner DS; Waxman K; Selam JL; Charles MA
    Int J Artif Organs; 1993 Dec; 16(12):847-54. PubMed ID: 8175202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients.
    Nathan DM; Dunn FL; Bruch J; McKitrick C; Larkin M; Haggan C; Lavin-Tompkins J; Norman D; Rogers D; Simon D
    Am J Med; 1996 Apr; 100(4):412-7. PubMed ID: 8610727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-insulin antibodies and metabolic deterioration after interruption of continuous subcutaneous insulin infusion.
    Scheen AJ; Henrivaux P; Jandrain B; Lefebvre PJ
    Diabetes Care; 1986; 9(6):673-4. PubMed ID: 3803158
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized study comparing blood glucose control and risk of severe hypoglycemia achieved by non-programmable versus programmable external insulin pumps.
    Catargi B; Breilh D; Gin H; Rigalleau V; Saux MC; Roger P; Tabarin A
    Diabetes Metab; 2001 Jun; 27(3):323-7. PubMed ID: 11431597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumps.
    Schaepelynck Bélicar P; Vague P; Lassmann-Vague V
    Diabetes Metab; 2003 Sep; 29(4 Pt 1):344-8. PubMed ID: 14526262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies.
    Lassmann-Vague V; Belicar P; Alessis C; Raccah D; Vialettes B; Vague P
    Diabet Med; 1996 Dec; 13(12):1051-5. PubMed ID: 8973887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy and Safety of Sensor Augmented Insulin Pump Therapy with Low-Glucose Suspend Feature in Patients with Type 1 Diabetes.
    Gómez AM; Marín Carrillo LF; Muñoz Velandia OM; Rondón Sepúlveda MA; Arévalo Correa CM; Mora Garzón E; Cuervo Diaz MC; Henao Carrillo DC
    Diabetes Technol Ther; 2017 Feb; 19(2):109-114. PubMed ID: 28001445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and future of implantable insulin pumps for the treatment of diabetes.
    Catargi B
    Expert Rev Med Devices; 2004 Nov; 1(2):181-5. PubMed ID: 16293038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
    Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
    Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump.
    Kessler L; Tritschler S; Bohbot A; Sigrist S; Karsten V; Boivin S; Dufour P; Belcourt A; Pinget M
    Diabetes Care; 2001 Feb; 24(2):302-7. PubMed ID: 11213883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmunity and intraperitoneal insulin treatment by programmable pumps: lack of relationship.
    Lassmann-Vague V; SanMarco M; LeJeune PJ; Alessis C; Vague P; Belicar P
    Diabetes Care; 1998 Nov; 21(11):2041-4. PubMed ID: 9802775
    [No Abstract]   [Full Text] [Related]  

  • 18. Substitution of basal delivery of insulin by proinsulin in type I diabetic patients under CSII.
    Kerner W; Wallmüller G; Beischer W; Pfeiffer EF
    Horm Metab Res Suppl; 1988; 18():74-7. PubMed ID: 3056816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes.
    Haardt MJ; Selam JL; Slama G; Bethoux JP; Dorange C; Mace B; Ramaniche ML; Bruzzo F
    Diabetes Care; 1994 Aug; 17(8):847-51. PubMed ID: 7956629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal insulin absorption after long-term intraperitoneal insulin therapy.
    Scavini M; Pincelli A; Petrella G; Galimberti G; Zager PG; Torri M; Pozza G
    Diabetes Care; 1995 Jan; 18(1):56-9. PubMed ID: 7698048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.